StreetAlpha.app
Home › Stocks › NKTR

Nektar Therapeutics (NKTR)

Healthcare
$35.91
▼ −1.45%
LAST CLOSE · NOV 17

Nektar Therapeutics is a San Francisco biopharmaceutical company developing immunotherapy drugs for autoimmune diseases and cancer. It last closed at $35.91 on Nov 17, down 1.45% on the day. NKTR last reported earnings on Thu, Nov 12, 2026. The average 12-month price target from 6 analysts is $104.17 (+190.1% from the last close), with a high of $178.00 and a low of $50.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (3 buy, 3 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in NKTR, 50% of them bullish and 50% bearish.

AI Auto Pilots
Is NKTR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$52.2M
−16.6% vs a year ago
Net income
−$177.3M
−339.7% margin
EPS (diluted)
−$6.19
Free cash flow
−$257.5M
−493.4% margin
Valuation
Market cap
$1.2B
34.2M shares
P/E
–
No P/E while losing money
Price to sales
23.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$34.7M
At Sep 30
Shareholder equity
$849.7M
Shares outstanding
34.2M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $101.9M$101.9MFY2021FY2022: $92.1M$92.1MFY2022FY2023: $90.1M$90.1MFY2023FY2024: $98.4M$98.4MFY2024FY2025: $55.2M$55.2MFY2025

From NKTR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · After the close (AMC)
Reported EPS
-$1.63
vs -$2.16 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±7.4%
Priced in before that report
Analyst consensus
Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
6firms
3 Buy3 Hold0 Sell
Each firm's latest rating on NKTR in the past 90 days
Average 12-month target
$104.17
▲ 190.1% upside

Based on 6 analysts who set a price target on NKTR in the past 90 days. The average target is $104.17, with a high of $178.00 and a low of $50.00, compared with the last close of $35.91.

Low $50.00Avg $104.17High $178.00
Blue marker: last close $35.91
Highest target$178.00
Average target$104.17
Lowest target$50.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 16Buy$153 → $149
UBSInitiated
Oct 12Hold$53
Leerink PartnersInitiated
Oct 12Buy$130
BTIGReiterated
Sep 25Buy$178
WedbushMaintained
Sep 23Hold$50
DateFirmActionRatingPrice target
Nov 16Canaccord GenuityTarget loweredBuy$153 → $149
Oct 12UBSInitiatedHold$53
Oct 12Leerink PartnersInitiatedBuy$130
Sep 25BTIGReiteratedBuy$178
Sep 23WedbushMaintainedHold$50
Loading…

Technical Analysis

NKTR · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 5% below its 20 day and 31% below its 50 day average. It is 81% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 34), near oversold. The nearest support is the swing low (Nov 5) at $35.81, and the nearest resistance the Pivot at $35.93.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 5.4%/day
Key levels
$109.0052 week high+203.5%
$65.04200 day average+81.1%
$59.41100 day average+65.4%
$46.9350 day average+30.7%
$39.04Swing high (Nov 11)+8.7%
$37.6820 day average+4.9%
$36.48Pivot R1+1.6%
$35.93Pivot+0.1%
$35.91Last close
$35.81Swing low (Nov 5)−0.3%
$35.36Pivot S1−1.5%
$33.4052 week low−7.0%
Indicators
RSI (14)34.43Weak, oversold below 30Neutral
MACD-2.45Above its signal lineBullish
Stochastic21.0Middle of its rangeNeutral
ADX (14)32.9Trending down
Williams %R-88.2Oversold below −80, overbought above −20Oversold
CCI (20)-194.6Oversold below −100, overbought above 100Oversold
Rate of change−4.9%Change over 10 sessionsBearish
ATR (14)$1.93Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NKTR

What happened before

See how NKTR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NKTR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NKTR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Sep 3 – Oct 5
Loading…

See today’s whale options flow across the market →

NKTR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●126 buying vs 112 selling
  • ●Held by funds -0.3 pts
  • ●Funds holding +0
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2442440.0%
In funds' top 1010100.0%
Held by funds104.8%105.1%−0.3 pts
New / increased39 / 8772 / 101−27.2%
Reduced / sold out71 / 4141 / 48+25.8%
Put/call ratio0.840.38+119.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NKTR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTR is in one of them and how their past NKTR trades turned out.

NKTR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NKTR in an article yet. Here's the latest on the wider market.

NKTR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Oct 2
Who traded NKTR · since 2018
Latest 2 filings
$1K – $15KTraded Jun 21, 2018Filed Oct 2, 2018
$1K – $15KTraded Jun 6, 2018Filed Oct 2, 2018
PersonTypeAmountTradedFiledDelay
Josh GottheimerD · NJSell$1K – $15KJun 21, 2018Oct 2, 2018103 d
Josh GottheimerD · NJBuy$1K – $15KJun 6, 2018Oct 2, 2018118 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California. It researches and develops drugs that act on the immune system, with programs aimed at autoimmune diseases such as atopic dermatitis and at cancer. Its main drug candidate, rezpegaldesleukin, is designed to increase the activity of regulatory T cells to help restore immune balance. The company's drugs are still in development, and they are intended for people living with autoimmune and inflammatory conditions.

Headquarters
San Francisco, CA
Founded
1990